Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: A pharmaceutical composition comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine that is stable to sterilization and suitable for topical application directly to tissue sites where the dermis has been breached, and has been sterilized, packaged compositions that have been sterilized, and methods of sterilizing these compositions are disclosed.

Abstract: An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide dissolved in water, buffer selected from citric acid, acetic acid, lactic acid, succinic acid, and tartaric acid, and optionally a tonicity adjuster, preferably selected from sorbitol and mannitol, wherein the pH is no greater than 6 and the formulation is sterile and preferably substantially free of sodium chloride.

Abstract: A pharmaceutical composition comprising 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine that is stable to sterilization and suitable for topical application directly to tissue sites where the dermis has been breached, and has been sterilized, packaged compositions that have been sterilized, and methods of sterilizing these compositions are disclosed.

Abstract: The present invention provides pharmaceutical compositions that include an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel. In another aspect, the present invention also provides a method of eliciting an antigen-specific immune response in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to generate an immune response in the subject against the antigen. In yet another aspect, the present invention also provides a method of treating a condition in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to ameliorate at least one symptom or clinical sign of the condition.

Abstract: An aqueous parenteral pharmaceutical formulation of the IRM drug compound N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide dissolved in water, buffer selected from citric acid, acetic acid, lactic acid, succinic acid, and tartaric acid, and optionally a tonicity adjuster, preferably selected from sorbitol and mannitol, wherein the pH is no greater than 6 and the formulation is sterile and preferably substantially free of sodium chloride.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: A method of preparing a tear-resistant composite sheet material having hydrophilic, absorptive particles enmeshed in a network of interlaced microfibrous polytetrafluoroethylene forming a fibril matrix, the hydrophilic absorptive particles having absorptive particles with absorptive capacity greater than 1.0 gram of water per gram of dry particle, wherein the method comprises:(1) dry blending one or more hydrophilic, absorptive particulate materials;(2) admixing water to particulate to form a damp mixture;(3) adding gradually, with stirring, to the mixture an equal weight of an aqueous emulsion of polytetrafluoroethylene;(4) mixing the mass to cause initial fibrillation of the polytetrafluoroethylene particles;(5) biaxially calendering the mass to produce a tear-resistant sheet having a tensile strength of at least 0.5 megapascal; and(6) drying the resultant sheet to remove water.

Abstract: A composite sheet material is highly absorbent toward aqueous fluids including blood and exudate and comprises a polytetrafluoroethylene fibril matrix and hydrophilic absorptive particles enmeshed in the matrix. The composite sheet material is useful as a wound dressing, as a drying material for non-aqueous solvents, and as a chromatographic material.

Abstract: A composite wound dressing, optionally having controlled permeability, is highly absorbent toward blood and exudate and comprises a polytetrafluoroethylene fibril matrix, hydrophilic absorptive particles enmeshed in the matrix, and, optionally, a partially occlusive film coated on one surface of the matrix.